| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 13, 2024 |
| Accession Number: | 0001193125-24-159212 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | $14.00 | Neutral | JP Morgan |
| 10/30/2023 | $23.00 | Neutral → Overweight | Piper Sandler |
| 8/10/2023 | $14.00 → $20.00 | Hold → Buy | Stifel |
| 1/4/2023 | $22.00 | Neutral → Buy | Guggenheim |
| 8/29/2022 | $25.00 | Outperform | Cowen |
| 8/5/2022 | $23.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 2/28/2022 | $11.00 → $6.00 | Equal-Weight → Underweight | Barclays |
| 12/1/2021 | $25.00 → $15.00 | Buy | HC Wainwright & Co. |
15-12G - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
EFFECT - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
Guggenheim analyst Michael Schmidt downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Neutral.
JMP Securities analyst Reni Benjamin downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Market Outperform to Market Perform.
In the last three months, 5 analysts have published ratings on Deciphera Pharmaceuticals (NASDAQ:DCPH), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 2 0 0 2M Ago 0 0 1 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Deciphera Pharmaceuticals, presenting an average target of $23.24, a high estimate of $26.00, and a low estimate of $16.00. Obse
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, CEO: Steven L. Hoerter, ", Deciphera", ))) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, Inc. ("Merger Sub"), established in the State of Delaware, United S
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Application (MAA) in the Third Quarter of 2024 – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company's MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being
OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, Chief Executive Officer: Steven L. Hoerter, ", Deciphera", ))) today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO (the "Acquisit
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, CEO: Steven L. Hoerter, ", Deciphera", ))) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, Inc. ("Merger Sub"), established in the State of Delaware, United S
OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, Chief Executive Officer: Steven L. Hoerter, ", Deciphera", ))) today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO (the "Acquisit
– Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA for Vimseltinib in the Second Quarter of 2024 and MAA in the Third Quarter of 2024 in Tenosynovial Giant Cell Tumor (TGCT) – – Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study in 2L GIST Patients with Mutations in KIT Exon 11+17/18 Published in Nature Medicine; Final Overall Survival (OS) Results from INTRIGUE Study in 2L GIST Patients Presented at ASCO GI – – Cash Expected to Fund Operating and Capital Expenditures into the Second Half of 2026 – Deciphera
JP Morgan resumed coverage of Deciphera Pharmaceuticals with a rating of Neutral and set a new price target of $14.00
Piper Sandler upgraded Deciphera Pharmaceuticals from Neutral to Overweight and set a new price target of $23.00
Stifel upgraded Deciphera Pharmaceuticals from Hold to Buy and set a new price target of $20.00 from $14.00 previously
A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Oct. 6, 2023 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that
— Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol, Ph.D., continues as Board Member — Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company's Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company. Dashyant Dhanak, Ph.D., has been appointed Executive Vice President and Chief Scientific Officer effective September 5, 2023. Dr. Dhanak brings over 30 year
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leading the Company's business development efforts as well as supporting corporate strategy initiatives. "We are thrilled to welcome Kelley to our executive team as Chief Business Officer. Kelley has extensive leadership experience in pharmaceutical and biotechnology companies with a proven track record of building value through business development and strategic partnerships," said Steve Hoerter, President and Ch